article thumbnail

Transgene and BioInvent report positive data for oncolytic virus

Pharmaceutical Technology

Analysis estimates that the oncolytic virus market will reach $1 billion by 2026. Transgene will be presenting new data at ASCO 2023 for its therapeutic cancer vaccines TG4001, in Phase II study in patients with HPV16-positive anogenital tumours ( NCT03260023 ), and TG4050, Phase I study in head and neck cancers ( NCT04183166 ).